Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 10—October 2016

Infection-Related Death among Persons with Refractory Juvenile Idiopathic Arthritis

Mario AbinunComments to Author , Jonathan P. Lane, Mark Wood1, Mark Friswell, Terence J. Flood, and Helen E. Foster
Author affiliations: Great North Children's Hospital, Newcastle upon Tyne, UK (M. Abinun, J.P. Lane, M. Friswell, T.J. Flood, H.E. Foster); Newcastle University, Newcastle upon Tyne (M. Abinun, H.E. Foster); Leeds General Infirmary, Leeds, UK (M. Wood)

Main Article

Table 2

Laboratory parameters of inflammatory activity for 2 children with juvenile idiopathic arthritis, Newcastle upon Tyne, United Kingdom, 2004*

Patient no., date CRP, mg/dL Ne, × 109 cells/L PLT, × 109/L ESR, mm/h Ferr, μg/L Fib, g/L TG, mmol/L Alb, g/L ALT, U/L Na, mmol/L
Patient 1
Feb 17 100 20.2 322 35 485 5.4 0.7 34 24 142
Feb 28 107 28.5 266 31 35 136
Feb 29 157 15.8 140 22 48 134
Mar 1

Patient 2
May 27 122 17.2 475 45 339 6.3 1.9 44 10 135
Jun 1 260 34.9 603 2815 8.0 38 23 137
Jun 6 365 37.5 710 105 7692 8.1 37 50 134
Jun 10 127 70.5 244 2.9 13 125 134

*Laboratory parameters for diagnosing macrophage activation syndrome: Ferr >684 μg/L and any 2 of the following signs: PLT count <181 × 109/L, ALT >48 U/L, TG >156 mg/dL, fibrinogen <360 mg/dL (14). See section in text on MAS versus Multiorgan Failure. Alb, serum albumin level (reference 38–53 g/L); ALT, serum alanine transaminase level (reference 0–40 U/L); CRP, C-reactive protein (reference 0–5 mg/dL); ESR, erythrocyte sedimentation rate (Westergren; reference 110 mm/h); Ferr, serum ferritin level (reference 20–60 μg/L); Fib, serum fibrinogen level (reference 1.5–4.0 g/L); Na, serum sodium level (reference 135–145 mmol/L); Ne, absolute neutrophil count; PLT, absolute platelet count; TG, serum triglyceride level (reference 0.5–1.8).

Main Article

  1. Prakken  B, Albani  S, Martini  A. Juvenile idiopathic arthritis. Lancet. 2011;377:213849.DOIPubMedGoogle Scholar
  2. Hinze  C, Gohar  F, Foell  D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11:290300.DOIPubMedGoogle Scholar
  3. Ringold  S, Weiss  PF, Beukelman  T, Dewitt  EM, Ilowite  NT, Kimura  Y, ; American College of Rheumatology. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Care Res (Hoboken). 2013;65:155163.DOIPubMedGoogle Scholar
  4. Southwood  TR. Paediatric rheumatic disease: Treatment of JIA in the biologic era: what are we waiting for? Nat Rev Rheumatol. 2014;10:1324.DOIPubMedGoogle Scholar
  5. Otten  MH, Prince  FH, Anink  J, Ten Cate  R, Hoppenreijs  EP, Armbrust  W, Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register. Ann Rheum Dis. 2013;72:7217.DOIPubMedGoogle Scholar
  6. Record  JL, Beukelman  T, Cron  RQ. Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. J Rheumatol. 2011;38:1801.DOIPubMedGoogle Scholar
  7. Woerner  A, Ritz  N. Infections in children treated with biological agents. Pediatr Infect Dis J. 2013;32:2848.DOIPubMedGoogle Scholar
  8. Hashkes  PJ, Uziel  Y, Laxer  RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol. 2010;6:56171.DOIPubMedGoogle Scholar
  9. Abinun  M. Haematopoietic stem cell transplantation for rheumatological conditions. Paediatr Child Health. 2011;21:55862 .DOIGoogle Scholar
  10. Abinun  M, Flood  TJ, Cant  AJ, Veys  P, Gennery  AR, Foster  HE, Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007). Mol Immunol. 2009;47:4651.DOIPubMedGoogle Scholar
  11. Milanetti  F, Abinun  M, Voltarelli  JC, Burt  RK. Autologous hematopoietic stem cell transplantation for childhood autoimmune disease. Pediatr Clin North Am. 2010;57:23971.DOIPubMedGoogle Scholar
  12. Myers  A, Clark  J, Foster  H. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346:6236.DOIPubMedGoogle Scholar
  13. Consolaro  A, Ruperto  N, Bracciolini  G, Frisina  A, Gallo  MC, Pistorio  A, ; Paediatric Rheumatology International Trials Organization (PRINTO). Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. Ann Rheum Dis. 2014;73:13803.DOIPubMedGoogle Scholar
  14. Ravelli  A, Minoia  F, Davì  S, Horne  A, Bovis  F, Pistorio  A, 2016 classification criteria for MAS complicating SO-JIA: EULAR/ACR/PPRINTO Initiative. Arthritis Rheumatol. 2016;68:56676.DOIPubMedGoogle Scholar
  15. Mermel  LA, Allon  M, Bouza  E, Craven  DE, Flynn  P, O’Grady  NP, Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.[ [Erratum in: Clin Infect Dis. 2010;50:457. Erratum in: Clin Infect Dis. 2010;50:1079. ]. Clin Infect Dis. 2009;49:145.DOIPubMedGoogle Scholar
  16. Minoia  F, Davì  S, Horne  A, Demirkaya  E, Bovis  F, Li  C, ; Pediatric Rheumatology International Trials Organization; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. Arthritis Rheumatol. 2014;66:31609.DOIPubMedGoogle Scholar
  17. Lovell  DJ, Zaoutis  TE, Sullivan  K. Immunosuppressants, infection, and inflammation. Clin Immunol. 2004;113:1379.DOIPubMedGoogle Scholar
  18. Beukelman  T, Xie  F, Chen  L, Baddley  JW, Delzell  E, Grijalva  CG, ; SABER Collaboration. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum. 2012;64:277380.DOIPubMedGoogle Scholar
  19. Kimura  Y, Weiss  JE, Haroldson  KL, Lee  T, Punaro  M, Oliveira  S, ; Childhood Arthritis Rheumatology Research Alliance Carra Net Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2013;65:74552.DOIPubMedGoogle Scholar
  20. van de Vosse  E, van Dissel  JT, Ottenhoff  TH. Genetic deficiencies of innate immune signalling in human infectious disease. Lancet Infect Dis. 2009;9:68898.DOIPubMedGoogle Scholar
  21. Abinun  M. An overview of infectious complications in children on new biologic response-modifying agents. Ped Health. 2010;4:50917 .DOIGoogle Scholar
  22. Maródi  L, Casanova  JL. Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. J Allergy Clin Immunol. 2010;126:9107.DOIPubMedGoogle Scholar
  23. Puel  A, Picard  C, Lorrot  M, Pons  C, Chrabieh  M, Lorenzo  L, Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-6. J Immunol. 2008;180:64754.DOIPubMedGoogle Scholar
  24. Swart  JF, de Roock  S, Wulffraat  NM. What are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis? Arthritis Res Ther. 2013;15:213.DOIPubMedGoogle Scholar
  25. Fitch  PG, Cron  RQ. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha. J Rheumatol. 2006;33:825, author reply 826–7.PubMedGoogle Scholar
  26. Renaud  C, Ovetchkine  P, Bortolozzi  P, Saint-Cyr  C, Tapiero  B. Fatal group A Streptococcus purpura fulminans in a child receiving TNF-α blocker. Eur J Pediatr. 2011;170:65760.DOIPubMedGoogle Scholar
  27. Toussi  SS, Pan  N, Walters  HM, Walsh  TJ. Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature. Clin Infect Dis. 2013;57:131830.DOIPubMedGoogle Scholar
  28. Elwood  RL, Pelszynski  MM, Corman  LI. Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J. 2003;22:2868.DOIPubMedGoogle Scholar
  29. Henderson  C, Goldbach-Mansky  R. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol. 2010;135:21022.DOIPubMedGoogle Scholar
  30. Cole  TS, Rogerson  E, Collins  J, Galloway  A, Clark  J. Central venous catheter-related blood stream infections in children undergoing hematopoietic stem cell transplant for primary immunodeficiency and other nonmalignant disorders. Pediatr Infect Dis J. 2011;30:1098100.DOIPubMedGoogle Scholar
  31. Eleftheriou  D, Melo  M, Marks  SD, Tullus  K, Sills  J, Cleary  G, Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford). 2009;48:97886.DOIPubMedGoogle Scholar
  32. Russell  RK, Wilson  ML, Loganathan  S, Bourke  B, Kiparissi  F, Mahdi  G, A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:94653.DOIPubMedGoogle Scholar
  33. Radhakrishna  SM, Reiff  AO, Marzan  KA, Azen  C, Khemani  RG, Rubin  S, Pediatric rheumatic disease in the intensive care unit: lessons learned from 15 years of experience in a tertiary care pediatric hospital. Pediatr Crit Care Med. 2012;13:e1816.DOIPubMedGoogle Scholar
  34. Shulman  AI, Punaro  M. Critical care of the pediatric patient with rheumatic disease. Curr Opin Pediatr. 2011;23:2638.DOIPubMedGoogle Scholar
  35. Thomas  E, Symmons  DP, Brewster  DH, Black  RJ, Macfarlane  GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30:95865.PubMedGoogle Scholar
  36. Hashkes  PJ, Wright  BM, Lauer  MS, Worley  SE, Tang  AS, Roettcher  PA, Mortality outcomes in pediatric rheumatology in the US. Arthritis Rheum. 2010;62:599608.PubMedGoogle Scholar
  37. Lionetti  G, Kimura  Y, Schanberg  LE, Beukelman  T, Wallace  CA, Ilowite  NT, Using registries to identify adverse events in rheumatic diseases. Pediatrics. 2013;132:e138494.DOIPubMedGoogle Scholar
  38. Ringold  S, Hendrickson  A, Abramson  L, Beukelman  T, Blier  PR, Bohnsack  J, Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. Arthritis Care Res (Hoboken). 2015;67:52937.DOIPubMedGoogle Scholar
  39. Ruperto  N, Brunner  HI, Quartier  P, Constantin  T, Wulffraat  N, Horneff  G, ; PRINTO; PRCSG. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396406.DOIPubMedGoogle Scholar
  40. De Benedetti  F, Brunner  HI, Ruperto  N, Kenwright  A, Wright  S, Calvo  I, ; PRINTO; PRCSG. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:238595.DOIPubMedGoogle Scholar
  41. van Royen-Kerkhof  A, Vastert  BS, Swart  JF, Wulffraat  NM. Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice? Immunotherapy. 2014;6:13.DOIPubMedGoogle Scholar
  42. Wahezi  DM, Ilowite  NT. Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives. Expert Opin Pharmacother. 2013;14:97589.DOIPubMedGoogle Scholar

Main Article

1Current affiliation: Leeds General Infirmary, Leeds, UK.

Page created: September 15, 2016
Page updated: September 15, 2016
Page reviewed: September 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.